Prostate cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:25:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Prostate cancer stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 BMS-986365 in Metastatic Castration-Sensitive Prostate Cancer in Patients with Suboptimal PSA Response After ADT and ARPI https://clinicaltrials.eu/trial/bms-986365-in-metastatic-castration-sensitive-prostate-cancer-in-patients-with-suboptimal-psa-response-after-adt-and-arpi/ Tue, 02 Jun 2026 09:56:41 +0000 https://clinicaltrials.eu/trial/bms-986365-in-metastatic-castration-sensitive-prostate-cancer-in-patients-with-suboptimal-psa-response-after-adt-and-arpi/ This clinical trial is studying metastatic castrate sensitive prostate cancer, a type of prostate cancer that has spread to other parts of the body but is still responding to hormone treatment. The study is testing BMS-986365, an oral capsule taken by mouth, to see whether switching from an androgen receptor pathway inhibitor to this treatment can help men whose PSA (prostate-specific antigen, a blood marker used to follow prostate cancer) has not dropped enough after about 7 months of androgen deprivation therapy and an androgen receptor pathway inhibitor.

The purpose of the study is to explore whether this treatment switch can improve the PSA response in this setting. In the study, participants first receive the standard hormone-based treatment, and then treatment is changed to BMS-986365. The study then follows how the cancer and symptoms change over time, while also checking for side effects, blood test changes, and heart tracing changes. The study also looks at general health and pain over the course of treatment.

]]>